Key facts
- This page summarizes Daniel Danny Cloutier's Form 4 filing for BRAIN SCIENTIFIC INC..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Aug 2022, 11:19.
Daniel Danny Cloutier - 10 Dec 2021 Form 4 Insider Report for BRAIN SCIENTIFIC INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2022, 11:19:49 UTC
- Prior SEC filing
- 25 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Cloutier
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel Danny Cloutier filed Form 4 for BRAIN SCIENTIFIC INC. on 25 Aug 2022.
Change
- Previous filing in this sequence was filed on 25 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BRSF
transaction
Derivative
Options to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +362,069
- Change %
- Price
- $0.000000
- Shares after
- 362,069
- Date
- 03 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 362,069
- Exercise price
- $0.2900
- Footnotes
- F1
BRSF
transaction
Derivative
Options to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +304,608
- Change %
- Price
- $0.000000
- Shares after
- 304,608
- Date
- 19 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 304,608
- Exercise price
- $0.1200
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The options were initially issued to Mr. Cloutier pursuant to a stock option agreement, dated December 10, 2021, whereby Mr. Cloutier was issued 61,140 options to purchase shares of common stock of the Issuer with an exercise price of $0.21. On February 3, 2022, the Issuer and Mr. Cloutier entered into an amended stock option agreement (the "Amendment") whereby (i) the number of options issued to Mr. Cloutier was amended to 362,069, and (ii) the exercise price was amended to $0.29. Pursuant to the Amendment, the options shall vest and become exercisable pursuant to the following schedule: 46,623 options vested and became exercisable on December 31, 2021, 89,277 options vested and became exercisable on March 31, 2022; 90,269 options shall become exercisable on June 30,2022, 91,261 options shall become exercisable on September 30,2022; and 44,639 options shall become exercisable on December 31, 2022.
Footnote F2
304,608 stock options (the "Options") were granted to Mr. Kukekov on August 19, 2022 (the "Date of Grant"), pursuant to the Brain Scientific 2022 Stock Incentive Plan. The Options shall vest and become exercisable on the following schedule: (i) 61,552 Options shall vest immediately, (ii) 69,444 Options shall vest on August 30, 2022, (iii) 69,444 Options shall vest on September 30, 2022, (iv) 69,444 Options shall vest on October 30, 2022, and (v) 34,724 Options shall vest on November 15, 2022.